Investor Presentaiton

Cardiovascular milvexian Camzyos MYK-224 Confidence in profile supports three parallel Phase 3 trials in SSP, ACS, and AF Phase 2 Phase 3 Projected Data Readout Indication Phase 1 Secondary Stroke Prevention LIBREXIA-STROKE¹ (Dose: 25mg BID) Acute Coronary Syndrome LIBREXIA-ACS² (Dose: 25mg BID) Atrial Fibrillation LIBREXIA -AF3 2026 2026 2027 The LIBREXIA Phase 3 studies represent the largest, most comprehensive program for a Factor Xla inhibitor U.S. FDA granted Fast Track designation to all 3 indications Ill Bristol Myers Squibb™ 1. NCT05702034; 2. NCT05754957; 3. NCT05757869 Not for Product Promotional Use 118

View entire presentation